New combo therapy aims to boost immune attack on Hard-to-Treat colorectal cancer
NCT ID NCT07467590
First seen Mar 27, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study tests a new treatment for people with advanced colorectal cancer that has not responded to standard therapies. Participants receive a special type of radiation (high and low dose) to some tumors, followed by a combination of targeted therapy (TKI) and immunotherapy (anti-PD-1). The goal is to see if this approach can shrink tumors and improve survival. About 33 adults with a specific type of colorectal cancer (MSS/pMMR) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE RESPONSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.